Menu

Engineered Hearts Beat

Human stem cells take up residence in mouse hearts stripped of their own components, restoring some of the organs’ function.

Aug 15, 2013
Kate Yandell

WIKIMEDIA, HUGO HEIKENWAELDERMouse hearts whose own cells were replaced with human stem cells were able to beat on their own, according to a paper published earlier this week (August 13) in Nature Communications. The beating isn’t yet strong enough to pump blood, but the results are encouraging for those seeking to engineer replacement organs for transplant.

“Our engineered hearts contain about 70 percent human heart precursor cells, which provide enough mechanical force for contraction,” Lei Yang, a biomedical engineer at the University of Pittsburgh and an author of the paper, told New Scientist.

Decellurizing organs and then seeding them with new cells is a promising approach in the race to engineer tissues and organs. The strategy could eventually allow researchers to supplement the transplant organ supply with donated human organs that were not fit for use as they were, or with animal organs. Doctors could even use a patient’s own stem cells for reconstituted organs, which could help protect patients from immune rejection.

To make their engineered heart, Yang and colleagues washed the cells out of mouse hearts with detergent. They then seeded the remaining extracellular matrix with human induced pluripotent stem cell (iPSC)-derived cardiovascular progenitor cells, which differentiated into cardiomyocytes, smooth muscle cells, and endothelial cells.

The mouse extracellular matrix helped stimulate proper differentiation and cell distribution throughout the heart, the authors said. The decellularization process left vascular channels, which gave the heart templates for building new blood vessels.

“Using our method, we could generate both muscle and vascular-like structures in the engineered heart constructs,” Yang told New Scientist.

After the cells were distributed and differentiated, the engineered hearts began to contract, though they did not beat as strongly as healthy hearts do. The reconstituted organs also lacked fibroblasts, which are ordinarily present in hearts.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.